Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Oscar B. Lahoud"'
Autor:
Malin Hultcrantz, Heather Landau, Sydney Lu, Sean M. Devlin, Ahmet Dogan, Sham Mailankody, Carlyn Tan, Michael Scordo, Oscar B Lahoud, Ola Landgren, Eric L. Smith, Meghan Salcedo, Caleb Ho, Urvi A Shah, Hani Hassoun, Neha Korde, Benjamin Diamond, Gunjan L. Shah, Donna Mastey, Maria E. Arcila, David J. Chung, Kelly Werner, Mikhail Roshal, Alexander M. Lesokhin, Andriy Derkach, Elizabet Tavitian, Sergio Giralt, Nikoletta Lendvai
Publikováno v:
American Journal of Hematology
Autor:
Neha Korde, Heather Landau, Obadi Obadi, Ruthee Bayer, Allison Parascondola, Malin Hultcrantz, Jennifer Acosta, Oscar B Lahoud, David J. Chung, Sham Mailankody, Saurabh Chhabra, Leeann Marcello, Christine S. Ferrer, Alexander M. Lesokhin, Sergio Giralt, Luciano J. Costa, Hani Hassoun, Gunjan L. Shah, Cesar Rodriguez, Susan Bal, Carlyn Tan, Jonathan Lambird, Leah Shulman, Urvi A Shah, Michael Scordo
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S158-S159
Background Despite major advances in multiple myeloma (MM) therapy, most patients relapse after primary treatment. We present the interim analysis of a phase II multicenter trial evaluating the efficacy of daratumumab, carfilzomib (27 mg/m2 twice wee
Autor:
Matthew S. Davids, Timothy J Voorhees, Anthony R. Mato, Toby A. Eyre, Haesook T. Kim, Craig S. Sauter, Gemlyn George, Sergio Giralt, Miguel-Angel Perales, Catherine C. Coombs, Harriet S. Walter, Jae H. Park, Lindsey E. Roeker, Andrew D. Zelenetz, Oscar B Lahoud, Steven T. Manchini, Danielle M. Brander, Alan P Skarbnik, Mark B. Geyer, Andrea Sitlinger, Peter Dreger, Kim Orchard, Nirav N. Shah, Jennifer R. Brown, Arvind Arumainathan
Publikováno v:
Blood Adv
Although novel agents (NAs) have improved outcomes for patients with chronic lymphocytic leukemia (CLL), a subset will progress through all available NAs. Understanding outcomes for potentially curative modalities including allogeneic hematopoietic s
Autor:
Eric Alden Smith, David J. Chung, Susan Bal, Malin Hultcrantz, Urvi A Shah, Ahmet Dogan, Hani Hassoun, Gunjan L. Shah, Nikoletta Lendvai, Heather Landau, Neha Korde, Oscar B Lahoud, Sean M. Devlin, Sham Mailankody, Scott T. Avecilla, Ola Landgren, Mikhail Roshal, Alexander M. Lesokhin, Parastoo B. Dahi, Michael Scordo, Sergio Giralt
Publikováno v:
Biol Blood Marrow Transplant
Autologous stem cell transplantation (ASCT) remains the standard of care for transplantation-eligible patients with multiple myeloma (MM). Bortezomib with lenalidomide and dexamethasone (VRD) is the most common triplet regimen for newly diagnosed MM
Autor:
Nikoletta Lendvai, Oscar B Lahoud, Hani Hassoun, Pamela Drullinsky, Gunjan L. Shah, Victoria Diab, Alexander M. Lesokhin, Donna Mastey, Heather Landau, Urvi A Shah, Malin Hultcrantz, Sham Mailankody, Ola Landgren, Sergio Giralt, Meghan Salcedo, Neha Korde, Eric L. Smith, Michael Scordo, David J. Chung, Julia Schlossman, Kelly Werner
Publikováno v:
Clin Lymphoma Myeloma Leuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23e67cb61a25106e82f0188cb09c5de1
https://europepmc.org/articles/PMC7405911/
https://europepmc.org/articles/PMC7405911/
Autor:
Gunjan L. Shah, Michael Scordo, David J. Chung, Heather Landau, Kazunori Murata, Oscar B Lahoud, Jenessa Holder, Sun Cho, Leeann Marcello, Sergio Giralt, Elizabeth Hoover, Parastoo B. Dahi
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S129-S130
Background Symptom burden after AHCT for multiple myeloma is highest at count nadir with elevation of inflammatory markers such as IL-6 as one potential etiology (Wang, 2014). We aimed to alleviate symptom burden post-AHCT using siltuximab (anti-IL-6
Autor:
Valkal Bhatt, Heather Landau, Michael Scordo, Andrew Lin, Sergio Giralt, Sean M. Devlin, Ryan Schofield, Oscar B Lahoud, David J. Chung, Alyssa Kamrowski, Gunjan L. Shah, Dean Carlow, Anthony J. Proli, Caroline A. Carino, Parastoo B. Dahi
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S154-S155
Background Body surface area-based dosing of melphalan prior to AHCT for MM and AL patients causes inter-patient variability in exposure measured by area under the curve (AUC). Higher AUC is associated with increased toxicity, but prolonged survival
Autor:
Angela Harrison, Dennis Verducci, Lakshmi V. Ramanathan, Venkata Yellapantula, Ola Landgren, Isabel Concepcion, Ciardello Amanda, Carlyn Tan, Maria E. Arcila, David J. Chung, Neha Korde, Caleb Ho, Benjamin Diamond, Hani Hassoun, Gunjan L. Shah, Sydney X. Lu, Aisara Chansakul, Mikhail Roshal, Alexander M. Lesokhin, Urvi A Shah, Ahmet Dogan, Heather Landau, Sham Mailankody, Julia Caple, Julia Schlossman, Kelly Werner, Andriy Derkach, Oscar B Lahoud, Meghan Salcedo, Malin Hultcrantz, Sergio Giralt, Jenna Rispoli, Michael Scordo, Francesco Maura, Allison Sams, Kazunori Murata, Even H Rustad, Katie Jones, Elizabet Tavitian, Tala Shekarkhand, Katie L. Thoren, Casey Piacentini
Publikováno v:
Blood. 136:7-7
INTRODUCTION. Recent studies show that ~25% of newly diagnosed multiple myeloma patients treated with 8 cycles of bortezomib, lenalidomide and dexamethasone (VRd) achieve minimal residual disease (MRD) negativity. Recently, 42% stringent complete res
Autor:
Anthony R. Mato, Catherine C. Coombs, Danielle M. Brander, Miguel-Angel Perales, Haesook T. Kim, Lindsey E. Roeker, Oscar B Lahoud, Steven T. Manchini, Sergio Giralt, Andrea Sitlinger, Harriet S. Walter, Toby A. Eyre, Timothy J Voorhees, Peter Dreger, Kim Orchard, Alan P Skarbnik, Craig S. Sauter, Jennifer R. Brown, Arvind Arumainathan
Publikováno v:
Blood. 134:3321-3321
Introduction: Prior to effective novel agent (NA) approval for CLL, alloHSCT was recommended for CLL patients (pts) with early relapse/refractory disease after purine-analogs or deletion 17p (del17p) or TP53 mutation (TP53mut) based on expert consens
Autor:
Hani Hassoun, Tim J Peterson, Oscar B Lahoud, Sham Mailankody, Gunjan L. Shah, Malin Hultcrantz, Neha Korde, Urvi A Shah, Heather Landau, Ola Landgren, Michael Scordo, Sydney X. Lu, Alexander M. Lesokhin, Eric L. Smith, Sergio Giralt
Publikováno v:
Blood. 134:5554-5554
Background: Several studies have indicated that the depth and duration of treatment response in multiple myeloma are both reduced in the relapsed setting. With further lines of therapy, responses continue to weaken in depth and shorten in duration. T